1.Treatment of depression fractures of posterolateral tibial plateau through a modified anterolateral approach.
Guo-Jian XU ; Dong WENG ; Ming-Hua XIE ; Wen-Qing LIANG ; Guan-Biao HU ; Yu QIAN
China Journal of Orthopaedics and Traumatology 2015;28(3):256-259
OBJECTIVETo study the therapeutic effects of posterolateral depression fractures of the tibial plateau through a modified anterolateral approach.
METHODSFrom February 2011 to January 2012,13 patients with posterolateral depression fractures of the tibial plateau were treated through a modified anterolateral approach. There were 8 males and 5 females, ranging in age from 28 to 59 years old (49.2 years old on average). Data from patients were collected retrospectively as follows: X-ray, time of fracture healing and the complications of fracture healing. The patients were evaluated both clinically and radiologically according to the Rasmussen score system.
RESULTSAll the patients were followed up, and the duration ranged from 6 to 18 months (mean 13.7 months). All the patients got bony union. The average radiographic bony union time was 15.1 weeks (ranged, 11 to 17 weeks). No case of secondary articular depression was found. No complications such as malunion or joint stiffness were found. But 1 patient had superficial infection and 1 patient had common peroneal nerve injury. According to the Rasmussen score system,the mean radiological score was 16.50 ± 0.67 (ranged, 13 to 18), and the mean functional score was 25.20 ± 2.21 (ranged, 13 to 30). The mean range of knee motion was (125.3 ± 9.3)° (ranged, 0° to 135°).
CONCLUSIONTreatment of depression fractures of posterolateral tibial plateau with a modified anterolateral approach is a safe method with effective exposure, due to its stable fixation and relatively good outcome with minimal soft-tissue complications. It is regarded as an ideal procedure for depression fractures of posterolateral tibial plateau.
Adult ; Female ; Fracture Fixation, Internal ; methods ; Fracture Healing ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Tibial Fractures ; surgery
2.Identification of Puumala like viruses in China.
Gang LIU ; Chuan LI ; Guang-wei HU ; Yue LI ; Lai-shun YAO ; Yu-qing CHEN ; Biao HUANG ; Ming REN ; Yun-zhi CHEN ; Shi-xin GUAN ; Chuan-you YU ; Bao-zhong NA ; Xiang-dong ZHONG ; Yue-xin SUN ; Wen-xue LI ; De-xin LI
Chinese Journal of Experimental and Clinical Virology 2003;17(1):55-57
BACKGROUNDTo confirm if Puumala like viruses exist in China.
METHODSRNA was extracted from lungs of bank voles captured in the Northeast China, partial S segments genome of Puumala viruses were amplified and sequenced.
RESULTS926 bp cDNA of S segments of Puumala like virus was amplified and sequenced. The phylogenetic analysis revealed that the Puumala like viruses found in China were most close to that found in Far East region of Russia.
CONCLUSIONSPuumala like virus does exist in Northeast China, and the nucleotides sequence of the viruses have high homolog to Puumala viruses found in Russia.
Animals ; China ; DNA, Viral ; analysis ; Hemorrhagic Fever with Renal Syndrome ; virology ; Lung ; virology ; Mice ; Phylogeny ; Puumala virus ; isolation & purification ; Sequence Analysis, DNA ; Sequence Homology, Nucleic Acid
3.Systematic review and sequential analysis of Xuebijing Injection in treatment of systemic inflammatory response syndrome.
Zhe ZHAO ; Shi-Xiang HU ; Jun-Fang GUAN ; Ji-Jie YI ; Zhi-Wei ZHANG ; Fang-Yuan CHEN ; Fang-Biao XU
China Journal of Chinese Materia Medica 2021;46(15):3980-3989
To systematically review the efficacy of Xuebijing Injection combined with western medicine in the treatment of systemic inflammatory response syndrome(SIRS). In this study, CBM, CNKI, Wanfang, VIP, PubMed and EMbase databases were retrieved for clinical randomized controlled trials on the effect of Xuebijing Injection combined with western medicine in the treatment of SIRS from the establishment of the database to July 31, 2020. After screening, Meta-analysis was conducted by RevMan 5.3 software, trial sequential analysis was conducted by TSA 0.9.5.10 beta software, and the evidence quality level was evaluated by GRADEprofiler 3.6.1 software. Meta-analysis showed that Xuebijing Injection combined with western medicine could reduce white blood cell count(MD=-2.32, 95%CI[-2.44,-2.21], P<0.000 01), C-reactive protein count(MD=-22.70, 95%CI[-29.61,-15.79], P<0.000 01), APACHE Ⅱ score(MD=-2.15, 95%CI[-2.43,-1.87], P<0.000 01), tumor necrosis factor alpha count(SMD=-1.23, 95%CI[-1.48,-0.99], P<0.000 01) and interleukin-6 count(SMD=-0.92, 95%CI[-1.15,-0.69], P<0.000 01), improve treatment efficiency(RR=1.39, 95%CI[1.23, 1.56], P<0.000 01), reduce incidence of multiple organ dysfunction(RR=0.47, 95%CI[0.35, 0.64], P<0.000 01) and mortality(RR=0.22, 95%CI[0.13, 0.37], P<0.000 01), which were better than western medicine treatment alone. Trial sequential analysis showed that in terms of reducing the incidence of multiple organ dysfunction and C-reactive protein count, the cumulative Z value passed through the traditional threshold, TSA threshold and expected information value, and reached the required number of cases. GRADE evaluation showed that the level of evidence was low or very low. According to the findings, Xuebijing Injection combined with western medicine is effective in treating SIRS. However, as the low quality of the included studies may affect the reliability of the conclusion, more high-quality studies shall be included for further verification in the future, so as to provide better suggestions for clinical medication.
Drugs, Chinese Herbal
;
Humans
;
Injections
;
Randomized Controlled Trials as Topic
;
Reproducibility of Results
;
Systemic Inflammatory Response Syndrome/drug therapy*